CLVLF OTC
Clinuvel Pharmaceuticals Limited
1W: -3.6%
1M: -3.4%
3M: -6.9%
YTD: -26.2%
1Y: -28.1%
3Y: -39.2%
5Y: -80.8%
$5.68
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$37M
-10.3% ▼
5Y CAGR: +13.9%
Capital Expenditures
$2M
-435.8% ▼
5Y CAGR: +13.4%
Free Cash Flow
$35M
-13.6% ▼
5Y CAGR: +13.9%
Dividends Paid
$3M
+0.1% ▲
Buybacks
$563K
-27.7% ▼
Net Change in Cash
-$6M
+13.7% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $21M | $31M | $36M | $0 | $34M |
| Depreciation & Amort. | $758K | $789K | $1M | $0 | $984K |
| Stock-Based Comp. | $6M | $9M | $0 | $0 | $0 |
| Change in Working Capital | $6M | -$3M | -$5M | $0 | -$3M |
| Other Non-Cash Items | $159K | $9M | $5M | $41M | $5M |
| Operating Cash Flow | $40M | $37M | $37M | $41M | $37M |
| — Investing Activities — | |||||
| Capital Expenditures | -$434K | -$1M | -$6M | -$299K | -$2M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | -$23M | -$47M | -$37M |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | $0 | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$434K | -$1M | -$29M | -$48M | -$39M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$268K | -$264K | -$347K | $0 | $0 |
| Stock Repurchased | $0 | $0 | -$5M | -$441K | -$563K |
| Dividends Paid | -$1M | -$2M | -$2M | -$3M | -$3M |
| Other Financing | $0 | $0 | $0 | -$183K | -$238K |
| Financing Cash Flow | -$2M | -$2M | -$4M | -$3M | -$3M |
| Net Change in Cash | $39M | $35M | $3M | -$7M | -$6M |
| Cash End of Period | $122M | $157M | $35M | $28M | $20M |
| Free Cash Flow | $39M | $36M | $31M | $41M | $35M |